Editas Medicine (EDIT) Misses Q4 EPS by 9c

Editas Medicine (NASDAQ: EDIT) reported Q4 EPS of ($0.84), $0.09 worse than the analyst estimate of ($0.75). Revenue for the quarter came in at $3.67 million versus the consensus estimate of $4.13 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• ADNOC Distribution agrees to buy Shell's South Africa unit for $1B
• bioAffinity Technologies Q2 CyPath Lung sales rise over 200% year-over-year